T. Rowe Price Associates
ACLX

T. Rowe Price Associates’s Arcellx ACLX Stock Holding History

T. Rowe Price Associates’s Portfolio ACLX Stock Details ACLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.28M Sell
45,954
-1,564,847
-97% -$138M ﹤0.01% 1403
2025
Q4 		$105M Buy
1,610,801
+346,750
+27% +$27.7M 0.01% 620
2025
Q3 		$104M Sell
1,264,051
-174,722
-12% -$12.6M 0.01% 612
2025
Q2 		$94.7M Sell
1,438,773
-400,851
-22% -$25M 0.01% 580
2025
Q1 		$121M Sell
1,839,624
-281,698
-13% -$19.1M 0.01% 518
2024
Q4 		$163M Buy
2,121,322
+220,711
+12% +$19.1M 0.02% 473
2024
Q3 		$159M Buy
1,900,611
+269,921
+17% +$18M 0.02% 479
2024
Q2 		$90M Buy
1,630,690
+286,137
+21% +$15.6M 0.01% 569
2024
Q1 		$93.5M Buy
1,344,553
+84,373
+7% +$5.35M 0.01% 565
2023
Q4 		$69.9M Buy
1,260,180
+323,309
+35% +$14.6M 0.01% 612
2023
Q3 		$33.6M Sell
936,871
-120,910
-11% -$4.17M ﹤0.01% 787
2023
Q2 		$33.4M Buy
1,057,781
+1,035,556
+4,659% +$39.6M ﹤0.01% 816
2023
Q1 		$686K Sell
22,225
-71,244
-76% -$2.16M ﹤0.01% 1972
2022
Q4 		$2.9M Buy
+93,469
New +$2.14M ﹤0.01% 1338

Other funds holding ACLX

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

T. Rowe Price Associates's ACLX Position: Q1 2026 in Review

T. Rowe Price Associates reduced its Arcellx (ACLX) stake by 97% in Q1 2026, selling an estimated $138M and leaving 45,954 shares worth $5.28M. The position accounts for ﹤0.01% of the portfolio, ranked #1403.

T. Rowe Price Associates first reported a position in ACLX in Q4 2022 and has held it in 14 quarters since. The position peaked at $163M in Q4 2024. 239 funds tracked by Wall St. Rank hold ACLX as of Q1 2026.

  • T. Rowe Price Associates held 45,954 shares of Arcellx worth $5.28M as of Q1 2026.
  • T. Rowe Price Associates sold 1,564,847 Arcellx shares in Q1 2026, an estimated $138M.
  • Arcellx made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #1403 holding.
  • T. Rowe Price Associates first reported a position in Arcellx in Q4 2022 and has held it in 14 quarters since.
  • T. Rowe Price Associates's Arcellx position peaked at $163M in Q4 2024.
  • 239 funds tracked by Wall St. Rank held Arcellx as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.